- Home
- ALDX vs GEVO Comparison
ALDX vs GEVO Comparison
Compare ALDX & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- GEVO
- Stock Information
- Founded
- ALDX 2004
- GEVO 2005
- Country
- ALDX United States
- GEVO United States
- Employees
- ALDX N/A
- GEVO N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- ALDX Health Care
- GEVO Industrials
- Exchange
- ALDX Nasdaq
- GEVO Nasdaq
- Market Cap
- ALDX 304.9M
- GEVO 330.4M
- IPO Year
- ALDX 2014
- GEVO 2011
- Fundamental
- Price
- ALDX $6.93
- GEVO $1.24
- Analyst Decision
- ALDX Strong Buy
- GEVO Buy
- Analyst Count
- ALDX 2
- GEVO 2
- Target Price
- ALDX $10.00
- GEVO $8.63
- AVG Volume (30 Days)
- ALDX 636.8K
- GEVO 3.9M
- Earning Date
- ALDX 05-01-2025
- GEVO 05-01-2025
- Dividend Yield
- ALDX N/A
- GEVO N/A
- EPS Growth
- ALDX N/A
- GEVO N/A
- EPS
- ALDX N/A
- GEVO N/A
- Revenue
- ALDX N/A
- GEVO $15,589,000.00
- Revenue This Year
- ALDX N/A
- GEVO N/A
- Revenue Next Year
- ALDX N/A
- GEVO $917.63
- P/E Ratio
- ALDX N/A
- GEVO N/A
- Revenue Growth
- ALDX N/A
- GEVO 16.59
- 52 Week Low
- ALDX $2.71
- GEVO $0.48
- 52 Week High
- ALDX $7.20
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- ALDX 62.09
- GEVO 34.26
- Support Level
- ALDX $6.79
- GEVO $1.19
- Resistance Level
- ALDX $7.20
- GEVO $1.28
- Average True Range (ATR)
- ALDX 0.55
- GEVO 0.11
- MACD
- ALDX 0.03
- GEVO -0.00
- Stochastic Oscillator
- ALDX 88.84
- GEVO 24.32
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.